The Swedish open-label diflunisal trial (DFNS01) on hereditary transthyretin amyloidosis and the impact of amyloid fibril composition

Jonas Wixner, Per Westermark, Elisabet Ihse, Björn Pilebro, Hans-Erik Lundgren & Intissar Anan

To cite this article: Jonas Wixner, Per Westermark, Elisabet Ihse, Björn Pilebro, Hans-Erik Lundgren & Intissar Anan (2019) The Swedish open-label diflunisal trial (DFNS01) on hereditary transthyretin amyloidosis and the impact of amyloid fibril composition, Amyloid, 26:sup1, 39-40, DOI: 10.1080/13506129.2019.1593133

To link to this article: https://doi.org/10.1080/13506129.2019.1593133

© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

Published online: 25 Jul 2019.

Submit your article to this journal

Article views: 73

View Crossmark data
The Swedish open-label diflunisal trial (DFNS01) on hereditary transthyretin amyloidosis and the impact of amyloid fibril composition

Jonas Wixner, Per Westermark, Elisabet Ihse, Björn Pilebro, Hans-Erik Lundgren, and Intissar Anana

Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden; Department of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden

Background

The non-steroidal anti-inflammatory drug diflunisal has been shown to stabilize transthyretin (TTR) and thereby prevent amyloid fibril formation. After the international randomized, double blind, placebo-controlled diflunisal trial [1] was closed for enrolment in 2011, the Swedish DFNS01 study was started to continue monitoring the effect of diflunisal in patients with hereditary transthyretin (ATTRm) amyloidosis. Since TTR amyloid fibril composition has been shown to be important for disease outcome [2], amyloid fibril type was taken into account when analysing the study results.

Material and methods

DFNS01 was a 24-month open-label observational study designed to monitor the effect of diflunisal 500 mg daily in ATTRm amyloidosis. It was open for enrolment from July 2011 to the publication of the controlled diflunisal trial. Primary outcome measure was changes in the Kumamoto scale [3], and secondary outcome measures were changes in nutritional status (modified body mass index (mBMI), p-albumin × BMI) [4], cardiac function (septal thickness, p-proBNP) and safety follow-up blood tests (b-haemoglobin, b-platelets, p-creatinine, p-liver enzymes). Evaluations were performed yearly. Amyloid fibril type was established from abdominal fat pad biopsies with Western blot analyses [2]. Late disease onset was defined as onset ≥50 years of age.

Results

Fifty-four patients were included and their baseline characteristics are shown in Table 1. Of those included, 14 (26%) had received diflunisal prior to inclusion in DFNS01 with a median pre-study treatment of 2 (full range 0.1–4) years.

Seventeen (31%) of the patients had completed the 24-month study follow-up, whereas 37 (69%) had dropped out after a median duration of 10.8 (0.4–21.8) months. Thirty-four patients had completed 12 months. The main reasons for early termination were study closure (40%), liver transplantation (24%), and side effects (19%).

Table 1. Baseline patient characteristics.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Completers (n = 17)</th>
<th>Non-completers (n = 37)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at inclusion (years)</td>
<td>69 (31–82)</td>
<td>67 (30–81)</td>
<td>.06</td>
</tr>
<tr>
<td>Duration of disease (years)</td>
<td>2.2 (0–10)</td>
<td>3.2 (0–11)</td>
<td>.66</td>
</tr>
<tr>
<td>Late disease onset (%)</td>
<td>60%</td>
<td>50%</td>
<td>.02</td>
</tr>
<tr>
<td>Male sex (%)</td>
<td>65%</td>
<td>65%</td>
<td>.02</td>
</tr>
<tr>
<td>TTR V30M mutation (%)</td>
<td>96%</td>
<td>100%</td>
<td>.31</td>
</tr>
<tr>
<td>Full-length amyloid fibrils (%)</td>
<td>42%</td>
<td>58%</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>Total Kumamoto score</td>
<td>13 (1–44)</td>
<td>10 (0–36)</td>
<td>.23</td>
</tr>
<tr>
<td>Cardiac septum thickness (mm)</td>
<td>16 (9–26)</td>
<td>13 (8–24)</td>
<td>&lt;.01</td>
</tr>
<tr>
<td>Modified BMI</td>
<td>1019 (651–1445)</td>
<td>972 (425–1494)</td>
<td>.66</td>
</tr>
<tr>
<td>Normal ECG (%)</td>
<td>35%</td>
<td>65%</td>
<td>.05</td>
</tr>
<tr>
<td>P-proBNP (ng/L)</td>
<td>643 (30–9622)</td>
<td>161 (22–6459)</td>
<td>.51</td>
</tr>
<tr>
<td>B-haemoglobin (g/L)</td>
<td>143 (115–165)</td>
<td>144 (121–160)</td>
<td>.52</td>
</tr>
<tr>
<td>B-platelets (10^9/L)</td>
<td>198 (127–324)</td>
<td>213 (145–331)</td>
<td>.08</td>
</tr>
<tr>
<td>P-creatinine (µmol/L)</td>
<td>68 (49–143)</td>
<td>75 (41–151)</td>
<td>.06</td>
</tr>
<tr>
<td>P-AST (µkat/L)</td>
<td>0.5 (0.3–1.0)</td>
<td>0.5 (0.3–1.4)</td>
<td>.14</td>
</tr>
<tr>
<td>P-ALT (µkat/L)</td>
<td>0.4 (0.1–1.1)</td>
<td>0.4 (0.1–2.5)</td>
<td>.84</td>
</tr>
</tbody>
</table>

TTR: transthyretin; BMI: body mass index; BNP: brain natriuretic peptide; AST: aspartate aminotransferase; ALT: alanine aminotransferase.

CONTACT Jonas Wixner, jonas.wixner@umu.se, Department of Medicine, Umeå University Hospital, Akutvägen 1, S-90185 Umeå, Sweden.

© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
transplanted patients, eight (89%) were males, eight (89%) had full-length amyloid fibrils only and seven (78%) had an early disease onset. The most frequent side effects were dyspepsia (12%), diarrhoea (9%) and increased p-creatinine (7%). For patients who had completed the study protocol, total Kumamoto scores had remained stable (median score 13 vs. 16 vs. 17.5, \(p = .21\)), as had the sub-scores for sensory neuropathy, autonomic neuropathy and organ dysfunction. However, motor neuropathy scores had increased slightly over time (0 vs. 2.5 vs. 4.5, \(p = .02\)). No significant changes were found for mBMI (1028 vs. 918 vs. 982, \(p = .06\)) or p-proBNP (532 vs. 412 vs. 457 ng/l, \(p = .19\)), whereas cardiac septum thickness had increased over time (16.5 vs. 16.5 vs. 18 mm, \(p = .01\)). No significant changes were found for those who had completed 12 months. Safety follow-up blood tests were stable at both the 12 and 24 month follow-ups. Among the seven patients who had completed the DFNS01 protocol, and received pre-study treatment with diflunisal, no significant changes were found for any of the outcome measures. Amyloid fibril type had been established in 42 (79%) patients, and 16 (38%) were of type A (fibrils consisting of both full-length and fragmented TTR). Type A patients were all late-onset cases (\(\geq 50\) years) and had a significantly higher pro-BNP, total Kumamoto score and septal thickness than type B patients at inclusion. Sub-group analyses showed no significant change over time in any of the outcome measures, neither for type A nor for type B patients.

**Discussion and conclusions**

Although limited by high dropout rates, mainly due to liver transplantation and study closure, the DFNS01 trial supports the safety and efficacy of diflunisal for ATTRm amyloidosis, and the results are in line with the previous placebo-controlled trial. Total Kumamoto scores and nutritional status remained stable, however, motor neuropathy scores and cardiac septum thickness increased significantly during the study, which suggests that complete disease stabilization is not achieved on group level. No obvious difference in outcome was noted with regard to amyloid fibril type, but the number of patients was low. Further studies are needed to evaluate the long-term effect of diflunisal and whether all sub-groups of patients have the same beneficial treatment effect.

**Disclosure statement**

No potential conflict of interest was reported by the authors.

**References**


